Study of the CD40 Agonistic Monoclonal Antibody APX005M

Conditions:   Cancer;   NSCLC;   Melanoma;   Urothelial Carcinoma;   MSI-H;   Head and Neck Cancer
Intervention:   Drug: APX005M
Sponsor:   Apexigen, Inc.
Recruiting - verified May 2017

http://ift.tt/2qB1qGe